XORTX Meets Nasdaq Continued Listing Requirements
Rhea-AI Summary
XORTX (NASDAQ: XRTX) received a Nasdaq letter of compliance on April 20, 2026, curing a prior deficiency under Nasdaq Rule 5550(a)(2) that requires a US$1.00 minimum bid price.
Following a 1-for-5 reverse share split implemented April 6, 2026, the company’s shares traded at or above US$1.00 for 10 consecutive trading days, meeting the requirement on April 17, 2026.
Positive
- Nasdaq compliance restored with letter received April 20, 2026
- Minimum bid requirement met after 10 consecutive trading days at or above US$1.00
- Reverse split effectively cured the listing deficiency
Negative
- Company executed a 1-for-5 reverse split on April 6, 2026
- Company previously failed to meet Nasdaq’s Minimum Bid Requirement before the reverse split
News Market Reaction – XRTX
On the day this news was published, XRTX gained 19.56%, reflecting a significant positive market reaction. Argus tracked a peak move of +38.3% during that session. Argus tracked a trough of -9.5% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $613K to the company's valuation, bringing the market cap to $3.75M at that time. Trading volume was exceptionally heavy at 130.5x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum data shows 3 biotech peers (e.g., TOVX, AZTR, ONCO) moving down together (median move about -3.0% per scanner summary), suggesting broader Healthcare/Biotech pressure while XRTX traded slightly lower by -0.88% ahead of this positive Nasdaq compliance news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 13 | Asset acquisition | Neutral | -1.8% | Closed acquisition of VB4-P5 kidney anti-fibrotic asset for US$3.0 million. |
| Apr 01 | Share consolidation detail | Neutral | +3.7% | Confirmed effective date and 1-for-5 terms of share consolidation on April 6. |
| Mar 26 | Consolidation date change | Neutral | +8.0% | Announced revised effective date for 1-for-5 share consolidation to April 6. |
| Mar 26 | Consolidation timing update | Neutral | +8.0% | Updated timing of previously disclosed share consolidation, pending approvals. |
| Mar 25 | Share consolidation plan | Neutral | -9.7% | Approved 1-for-5 consolidation to help meet Nasdaq’s US$1.00 bid requirement. |
Recent news centered on share consolidation to maintain Nasdaq listing and an asset acquisition, with share price reactions mixed across these corporate actions.
Over the past month, XRTX focused on maintaining its Nasdaq listing via a 1-for-5 share consolidation and related shareholder approvals, as reflected in multiple announcements from Mar 24–Apr 6, 2026. The company also closed a kidney anti-fibrotic asset acquisition for US$3.0 million on Apr 13, 2026. Today’s confirmation that Nasdaq’s minimum bid requirement has been cured follows this sequence of governance and capital-structure steps aimed at continued listing.
Market Pulse Summary
The stock surged +19.6% in the session following this news. A strong positive reaction aligns with news that Nasdaq’s minimum bid deficiency has been cured after a 1-for-5 reverse split and 10-day trading requirement above US$1.00. Historically, XRTX’s consolidation and governance updates produced mixed but sometimes favorable moves. Investors would still need to weigh ongoing clinical, funding and broader biotech sector risks when assessing how durable any sharp upside move might be.
Key Terms
minimum bid price regulatory
minimum bid requirement regulatory
reverse split financial
AI-generated analysis. Not financial advice.
CALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that it has received a letter of compliance from the Nasdaq Stock Market LLC’s ("Nasdaq”) Listing Qualifications Department in connection with Nasdaq Rule 5550(a)(2) that requires a listed company’s shares to maintain a minimum bid price of US
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy and recently acquired VB4-P5 program, which is currently at the pre-IND stage of development and targets both rare and prevalent forms of kidney disease. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at www.xortx.com.
For more information, please contact:
| Allen Davidoff, CEO | Nick Rigopulos, Director of Communications |
| adavidoff@xortx.com | nick@alpineequityadv.com |
| +1 403 455 7727 | +1 617 901 0785 |
Forward Looking Statements
This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to our ongoing compliance with Nasdaq listing standards; the success and timing of our preclinical studies and clinical trials; our plans to develop and commercialize our product candidates; and our plans to advance research in other kidney disease applications. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.
